دورية أكاديمية
أعرض في EDS

Phenotypically Silent Bone Morphogenetic Protein Receptor 2 Mutations Predispose Rats to Inflammation-Induced Pulmonary Arterial Hypertension by Enhancing the Risk for Neointimal Transformation.

التفاصيل البيبلوغرافية
العنوان: Phenotypically Silent Bone Morphogenetic Protein Receptor 2 Mutations Predispose Rats to Inflammation-Induced Pulmonary Arterial Hypertension by Enhancing the Risk for Neointimal Transformation.
المؤلفون: Tian W; Veterans Affairs Palo Alto Health Care System, CA (W.T, X.J., Y.K.S., E.S., A.B.T., G.P., Y.K., P.Z., S.P., P.D., M.R.N.).; Stanford University School of Medicine, CA (W.T., X.J., Y.K.S., E.S., T.H.W., P.N.K., A.B.T., A.C., L.W., G.P., Y.K., P.Z., J.C., S.P., P.D., P.M., H.C., R.Z., M.P.S., M.R., M.R.N.)., Jiang X; Veterans Affairs Palo Alto Health Care System, CA (W.T, X.J., Y.K.S., E.S., A.B.T., G.P., Y.K., P.Z., S.P., P.D., M.R.N.).; Stanford University School of Medicine, CA (W.T., X.J., Y.K.S., E.S., T.H.W., P.N.K., A.B.T., A.C., L.W., G.P., Y.K., P.Z., J.C., S.P., P.D., P.M., H.C., R.Z., M.P.S., M.R., M.R.N.)., Sung YK; Veterans Affairs Palo Alto Health Care System, CA (W.T, X.J., Y.K.S., E.S., A.B.T., G.P., Y.K., P.Z., S.P., P.D., M.R.N.).; Stanford University School of Medicine, CA (W.T., X.J., Y.K.S., E.S., T.H.W., P.N.K., A.B.T., A.C., L.W., G.P., Y.K., P.Z., J.C., S.P., P.D., P.M., H.C., R.Z., M.P.S., M.R., M.R.N.)., Shuffle E; Veterans Affairs Palo Alto Health Care System, CA (W.T, X.J., Y.K.S., E.S., A.B.T., G.P., Y.K., P.Z., S.P., P.D., M.R.N.).; Stanford University School of Medicine, CA (W.T., X.J., Y.K.S., E.S., T.H.W., P.N.K., A.B.T., A.C., L.W., G.P., Y.K., P.Z., J.C., S.P., P.D., P.M., H.C., R.Z., M.P.S., M.R., M.R.N.)., Wu TH; Stanford University School of Medicine, CA (W.T., X.J., Y.K.S., E.S., T.H.W., P.N.K., A.B.T., A.C., L.W., G.P., Y.K., P.Z., J.C., S.P., P.D., P.M., H.C., R.Z., M.P.S., M.R., M.R.N.)., Kao PN; Stanford University School of Medicine, CA (W.T., X.J., Y.K.S., E.S., T.H.W., P.N.K., A.B.T., A.C., L.W., G.P., Y.K., P.Z., J.C., S.P., P.D., P.M., H.C., R.Z., M.P.S., M.R., M.R.N.)., Tu AB; Veterans Affairs Palo Alto Health Care System, CA (W.T, X.J., Y.K.S., E.S., A.B.T., G.P., Y.K., P.Z., S.P., P.D., M.R.N.).; Stanford University School of Medicine, CA (W.T., X.J., Y.K.S., E.S., T.H.W., P.N.K., A.B.T., A.C., L.W., G.P., Y.K., P.Z., J.C., S.P., P.D., P.M., H.C., R.Z., M.P.S., M.R., M.R.N.)., Dorfmüller P; Faculté de Médecine, Université Paris-Sud and Université Paris-Saclay, Le Kremlin-Bicêtre, France (P.D., M.H.).; Institut National de la Sante Et de la Recherche Medicale UMR_S 999, Le Plessis-Robinson, France (P.D., M.H.).; Pathology Department, Hôpital Marie Lannelongue, Le Plessis-Robinson, Paris, France (P.D.)., Cao A; Stanford University School of Medicine, CA (W.T., X.J., Y.K.S., E.S., T.H.W., P.N.K., A.B.T., A.C., L.W., G.P., Y.K., P.Z., J.C., S.P., P.D., P.M., H.C., R.Z., M.P.S., M.R., M.R.N.)., Wang L; Stanford University School of Medicine, CA (W.T., X.J., Y.K.S., E.S., T.H.W., P.N.K., A.B.T., A.C., L.W., G.P., Y.K., P.Z., J.C., S.P., P.D., P.M., H.C., R.Z., M.P.S., M.R., M.R.N.)., Peng G; Veterans Affairs Palo Alto Health Care System, CA (W.T, X.J., Y.K.S., E.S., A.B.T., G.P., Y.K., P.Z., S.P., P.D., M.R.N.).; Stanford University School of Medicine, CA (W.T., X.J., Y.K.S., E.S., T.H.W., P.N.K., A.B.T., A.C., L.W., G.P., Y.K., P.Z., J.C., S.P., P.D., P.M., H.C., R.Z., M.P.S., M.R., M.R.N.).; State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, China (G.P.)., Kim Y; Veterans Affairs Palo Alto Health Care System, CA (W.T, X.J., Y.K.S., E.S., A.B.T., G.P., Y.K., P.Z., S.P., P.D., M.R.N.).; Stanford University School of Medicine, CA (W.T., X.J., Y.K.S., E.S., T.H.W., P.N.K., A.B.T., A.C., L.W., G.P., Y.K., P.Z., J.C., S.P., P.D., P.M., H.C., R.Z., M.P.S., M.R., M.R.N.)., Zhang P; Veterans Affairs Palo Alto Health Care System, CA (W.T, X.J., Y.K.S., E.S., A.B.T., G.P., Y.K., P.Z., S.P., P.D., M.R.N.).; Stanford University School of Medicine, CA (W.T., X.J., Y.K.S., E.S., T.H.W., P.N.K., A.B.T., A.C., L.W., G.P., Y.K., P.Z., J.C., S.P., P.D., P.M., H.C., R.Z., M.P.S., M.R., M.R.N.)., Chappell J; Stanford University School of Medicine, CA (W.T., X.J., Y.K.S., E.S., T.H.W., P.N.K., A.B.T., A.C., L.W., G.P., Y.K., P.Z., J.C., S.P., P.D., P.M., H.C., R.Z., M.P.S., M.R., M.R.N.)., Pasupneti S; Veterans Affairs Palo Alto Health Care System, CA (W.T, X.J., Y.K.S., E.S., A.B.T., G.P., Y.K., P.Z., S.P., P.D., M.R.N.).; Stanford University School of Medicine, CA (W.T., X.J., Y.K.S., E.S., T.H.W., P.N.K., A.B.T., A.C., L.W., G.P., Y.K., P.Z., J.C., S.P., P.D., P.M., H.C., R.Z., M.P.S., M.R., M.R.N.)., Dahms P; Veterans Affairs Palo Alto Health Care System, CA (W.T, X.J., Y.K.S., E.S., A.B.T., G.P., Y.K., P.Z., S.P., P.D., M.R.N.).; Stanford University School of Medicine, CA (W.T., X.J., Y.K.S., E.S., T.H.W., P.N.K., A.B.T., A.C., L.W., G.P., Y.K., P.Z., J.C., S.P., P.D., P.M., H.C., R.Z., M.P.S., M.R., M.R.N.)., Maguire P; Stanford University School of Medicine, CA (W.T., X.J., Y.K.S., E.S., T.H.W., P.N.K., A.B.T., A.C., L.W., G.P., Y.K., P.Z., J.C., S.P., P.D., P.M., H.C., R.Z., M.P.S., M.R., M.R.N.)., Chaib H; Stanford University School of Medicine, CA (W.T., X.J., Y.K.S., E.S., T.H.W., P.N.K., A.B.T., A.C., L.W., G.P., Y.K., P.Z., J.C., S.P., P.D., P.M., H.C., R.Z., M.P.S., M.R., M.R.N.)., Zamanian R; Stanford University School of Medicine, CA (W.T., X.J., Y.K.S., E.S., T.H.W., P.N.K., A.B.T., A.C., L.W., G.P., Y.K., P.Z., J.C., S.P., P.D., P.M., H.C., R.Z., M.P.S., M.R., M.R.N.)., Peters-Golden M; University of Michigan Health System, Ann Arbor (M.P.G.)., Snyder MP; Stanford University School of Medicine, CA (W.T., X.J., Y.K.S., E.S., T.H.W., P.N.K., A.B.T., A.C., L.W., G.P., Y.K., P.Z., J.C., S.P., P.D., P.M., H.C., R.Z., M.P.S., M.R., M.R.N.)., Voelkel NF; Free University Medical Center Amsterdam, the Netherlands (N.F.V.)., Humbert M; Faculté de Médecine, Université Paris-Sud and Université Paris-Saclay, Le Kremlin-Bicêtre, France (P.D., M.H.).; Institut National de la Sante Et de la Recherche Medicale UMR_S 999, Le Plessis-Robinson, France (P.D., M.H.).; AP-HP, Service de Pneumologie, Centre de Référence de l'Hypertension Pulmonaire Sévère, Department Hospitalo-Universitaire Thorax Innovation, Hôpital de Bicêtre, Le Kremlin-Bicêtre, France (M.H.)., Rabinovitch M; Stanford University School of Medicine, CA (W.T., X.J., Y.K.S., E.S., T.H.W., P.N.K., A.B.T., A.C., L.W., G.P., Y.K., P.Z., J.C., S.P., P.D., P.M., H.C., R.Z., M.P.S., M.R., M.R.N.)., Nicolls MR; Veterans Affairs Palo Alto Health Care System, CA (W.T, X.J., Y.K.S., E.S., A.B.T., G.P., Y.K., P.Z., S.P., P.D., M.R.N.).; Stanford University School of Medicine, CA (W.T., X.J., Y.K.S., E.S., T.H.W., P.N.K., A.B.T., A.C., L.W., G.P., Y.K., P.Z., J.C., S.P., P.D., P.M., H.C., R.Z., M.P.S., M.R., M.R.N.).
المصدر: Circulation [Circulation] 2019 Oct 22; Vol. 140 (17), pp. 1409-1425. Date of Electronic Publication: 2019 Aug 29.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 0147763 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1524-4539 (Electronic) Linking ISSN: 00097322 NLM ISO Abbreviation: Circulation Subsets: MEDLINE
أسماء مطبوعة: Publication: Hagerstown, MD : Lippincott Williams & Wilkins
Original Publication: [Dallas, Tex., etc., American Heart Association, etc.]
مواضيع طبية MeSH: Bone Morphogenetic Protein Receptors, Type II/*genetics , Inflammation/*metabolism , Neointima/*metabolism , Pulmonary Arterial Hypertension/*physiopathology, Animals ; Endothelial Cells/metabolism ; Hypertension, Pulmonary/physiopathology ; Myocytes, Smooth Muscle/metabolism ; Pulmonary Arterial Hypertension/genetics ; Pulmonary Artery/pathology ; Pulmonary Artery/physiopathology ; Rats, Transgenic ; Signal Transduction/physiology
مستخلص: Background: Bmpr2 (bone morphogenetic protein receptor 2) mutations are critical risk factors for hereditary pulmonary arterial hypertension (PAH) with approximately 20% of carriers developing disease. There is an unmet medical need to understand how environmental factors, such as inflammation, render Bmpr2 mutants susceptible to PAH. Overexpressing 5-LO (5-lipoxygenase) provokes lung inflammation and transient PAH in Bmpr2 +/ - mice. Accordingly, 5-LO and its metabolite, leukotriene B 4 , are candidates for the second hit. The purpose of this study was to determine how 5-LO-mediated pulmonary inflammation synergized with phenotypically silent Bmpr2 defects to elicit significant pulmonary vascular disease in rats.
Methods: Monoallelic Bmpr2 mutant rats were generated and found phenotypically normal for up to 1 year of observation. To evaluate whether a second hit would elicit disease, animals were exposed to 5-LO-expressing adenovirus, monocrotaline, SU5416, SU5416 with chronic hypoxia, or chronic hypoxia alone. Bmpr2 -mutant hereditary PAH patient samples were assessed for neointimal 5-LO expression. Pulmonary artery endothelial cells with impaired BMPR2 signaling were exposed to increased 5-LO-mediated inflammation and were assessed for phenotypic and transcriptomic changes.
Results: Lung inflammation, induced by intratracheal delivery of 5-LO-expressing adenovirus, elicited severe PAH with intimal remodeling in Bmpr2 +/- rats but not in their wild-type littermates. Neointimal lesions in the diseased Bmpr2 +/- rats gained endogenous 5-LO expression associated with elevated leukotriene B 4 biosynthesis. Bmpr2 -mutant hereditary PAH patients similarly expressed 5-LO in the neointimal cells. In vitro, BMPR2 deficiency, compounded by 5-LO-mediated inflammation, generated apoptosis-resistant and proliferative pulmonary artery endothelial cells with mesenchymal characteristics. These transformed cells expressed nuclear envelope-localized 5-LO consistent with induced leukotriene B 4 production, as well as a transcriptomic signature similar to clinical disease, including upregulated nuclear factor Kappa B subunit (NF-κB), interleukin-6, and transforming growth factor beta (TGF-β) signaling pathways. The reversal of PAH and vasculopathy in Bmpr2 mutants by TGF-β antagonism suggests that TGF-β is critical for neointimal transformation.
Conclusions: In a new 2-hit model of disease, lung inflammation induced severe PAH pathology in Bmpr2 +/- rats. Endothelial transformation required the activation of canonical and noncanonical TGF-β signaling pathways and was characterized by 5-LO nuclear envelope translocation with enhanced leukotriene B 4 production. This study offers an explanation of how an environmental injury unleashes the destructive potential of an otherwise silent genetic mutation.
References: Circulation. 2014 Feb 11;129(6):692-703. (PMID: 24201301)
Am J Respir Crit Care Med. 2012 Feb 1;185(3):311-21. (PMID: 22108206)
Trends Cardiovasc Med. 2011 Aug;21(6):166-71. (PMID: 22814424)
Eur Respir J. 2019 Jan 24;53(1):null. (PMID: 30545973)
Circ Res. 2006 Feb 3;98(2):209-17. (PMID: 16357305)
Nat Med. 2014 Nov;20(11):1289-300. (PMID: 25344740)
N Engl J Med. 2007 Nov 1;357(18):1841-54. (PMID: 17978293)
Biochem Biophys Res Commun. 2006 Oct 6;348(4):1403-10. (PMID: 16919603)
Circulation. 2016 May 3;133(18):1783-94. (PMID: 27045138)
Am J Respir Crit Care Med. 1998 Jan;157(1):219-29. (PMID: 9445303)
Front Pharmacol. 2010 Dec 24;1:143. (PMID: 21833182)
Nat Med. 2015 Jul;21(7):777-85. (PMID: 26076038)
Circ Res. 2011 Sep 30;109(8):867-79. (PMID: 21868697)
Sci Transl Med. 2013 Aug 28;5(200):200ra117. (PMID: 23986401)
J Mech Behav Biomed Mater. 2013 Jan;17:307-16. (PMID: 23122714)
Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12165-70. (PMID: 14530386)
Nat Rev Mol Cell Biol. 2012 Oct;13(10):616-30. (PMID: 22992590)
Hypertension. 2014 Jun;63(6):1260-9. (PMID: 24614212)
Circ Res. 2014 Jun 20;115(1):165-75. (PMID: 24951765)
Am J Physiol Lung Cell Mol Physiol. 2012 May 15;302(10):L977-91. (PMID: 22307907)
Am J Respir Cell Mol Biol. 2019 Jun;60(6):637-649. (PMID: 30562042)
Circ Res. 2018 Jun 8;122(12):1689-1702. (PMID: 29545367)
Stem Cells Int. 2017;2017:7108458. (PMID: 29138638)
Circulation. 2013 Sep 17;128(12):1354-64. (PMID: 23958565)
Am J Respir Crit Care Med. 2015 Jun 1;191(11):1273-86. (PMID: 25853696)
Am J Respir Crit Care Med. 2012 Nov 1;186(9):892-6. (PMID: 22923661)
J Biol Chem. 2003 Jun 13;278(24):21989-97. (PMID: 12663671)
J Lipid Res. 2009 Apr;50 Suppl:S40-5. (PMID: 18987389)
Biochem J. 2011 Aug 1;437(3):515-20. (PMID: 21585337)
J Cell Biochem. 2007 May 1;101(1):9-33. (PMID: 17340614)
N Engl J Med. 2001 Aug 2;345(5):319-24. (PMID: 11484688)
J Exp Med. 2014 Feb 10;211(2):263-80. (PMID: 24446489)
Circ Res. 2009 May 22;104(10):1184-91. (PMID: 19390056)
Circ Res. 2019 Mar 15;124(6):904-919. (PMID: 30661465)
FASEB J. 2001 Feb;15(2):427-38. (PMID: 11156958)
Clin Transl Sci. 2010 Oct;3(5):210-8. (PMID: 20973920)
Eur Respir J. 2019 Jan 24;53(1):null. (PMID: 30545970)
Am J Physiol Heart Circ Physiol. 2002 Feb;282(2):H585-93. (PMID: 11788406)
Circulation. 2015 Mar 17;131(11):1006-18. (PMID: 25593290)
Nat Rev Drug Discov. 2012 Oct;11(10):790-811. (PMID: 23000686)
Circulation. 2005 Jul 26;112(4):553-62. (PMID: 16027259)
Proc Natl Acad Sci U S A. 2000 May 9;97(10):5261-6. (PMID: 10779545)
Hypertension. 2015 Dec;66(6):1227-1239. (PMID: 26558820)
Circulation. 2019 Feb 12;139(7):932-948. (PMID: 30586714)
Am J Respir Crit Care Med. 2015 Aug 1;192(3):356-66. (PMID: 26030479)
Lancet Respir Med. 2016 Feb;4(2):129-37. (PMID: 26795434)
Circ Res. 2006 Mar 31;98(6):818-27. (PMID: 16497988)
J Clin Invest. 2011 Nov;121(11):4548-66. (PMID: 22005303)
معلومات مُعتمدة: R01 HL095686 United States HL NHLBI NIH HHS; R01 HL138473 United States HL NHLBI NIH HHS; R01 HL074186 United States HL NHLBI NIH HHS; R56 HL082662 United States HL NHLBI NIH HHS; K12 HL120001 United States HL NHLBI NIH HHS; R01 HL122887 United States HL NHLBI NIH HHS; T32 HL129970 United States HL NHLBI NIH HHS; S10 OD020141 United States OD NIH HHS; R01 HL125739 United States HL NHLBI NIH HHS; R01 HL082662 United States HL NHLBI NIH HHS; P01 HL014985 United States HL NHLBI NIH HHS
فهرسة مساهمة: Keywords: bmpr2 receptor; endothelial cells; inflammation; lung
المشرفين على المادة: EC 2.7.11.30 (Bone Morphogenetic Protein Receptors, Type II)
تواريخ الأحداث: Date Created: 20190830 Date Completed: 20200617 Latest Revision: 20201022
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC6803052
DOI: 10.1161/CIRCULATIONAHA.119.040629
PMID: 31462075
قاعدة البيانات: MEDLINE
الوصف
تدمد:1524-4539
DOI:10.1161/CIRCULATIONAHA.119.040629